In Vivo Mononuclear Cell Tracking Using Superparamagnetic Particles of Iron Oxide: Feasibility and Safety in Humans

Background— Cell therapy is an emerging and exciting novel treatment option for cardiovascular disease that relies on the delivery of functional cells to their target site. Monitoring and tracking cells to ensure tissue delivery and engraftment is a critical step in establishing clinical and therapeutic efficacy. The study aims were (1) to develop a Good Manufacturing Practice–compliant method of labeling competent peripheral blood mononuclear cells with superparamagnetic particles of iron oxide (SPIO), and (2) to evaluate its potential for magnetic resonance cell tracking in humans. Methods and Results— Peripheral blood mononuclear cells 1–5×109 were labeled with SPIO. SPIO-labeled cells had similar in vitro viability, migratory capacity, and pattern of cytokine release to unlabeled cells. After intramuscular administration, up to 108 SPIO-labeled cells were readily identifiable in vivo for at least 7 days using magnetic resonance imaging scanning. Using a phased-dosing study, we demonstrated that systemic delivery of up to 109 SPIO-labeled cells in humans is safe, and cells accumulating in the reticuloendothelial system were detectable on clinical magnetic resonance imaging. In a healthy volunteer model, a focus of cutaneous inflammation was induced in the thigh by intradermal injection of tuberculin. Intravenously delivered SPIO-labeled cells tracked to the inflamed skin and were detectable on magnetic resonance imaging. Prussian blue staining of skin biopsies confirmed iron-laden cells in the inflamed skin. Conclusions— Human peripheral blood mononuclear cells can be labeled with SPIO without affecting their viability or function. SPIO labeling for magnetic resonance cell tracking is a safe and feasible technique that has major potential for a range of cardiovascular applications including monitoring of cell therapies and tracking of inflammatory cells. Clinical Trial Registration— URL: http://www.clinicaltrials.gov; Unique identifier: NCT00972946, NCT01169935.

[1]  Piotr Walczak,et al.  Tracking stem cells using magnetic nanoparticles. , 2011, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[2]  K. Jeong,et al.  Homing of adipose-derived stem cells to radiofrequency catheter ablated canine atrium and differentiation into cardiomyocyte-like cells. , 2011, International journal of cardiology.

[3]  Q. Pankhurst,et al.  Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. , 2009, Cancer research.

[4]  G. Teng,et al.  In Vivo Tracking of Dual‐Labeled Mesenchymal Stem Cells Homing Into the Injured Common Carotid Artery , 2009, Anatomical record.

[5]  Fei Li,et al.  In vitro labeling of human umbilical cord mesenchymal stem cells with superparamagnetic iron oxide nanoparticles , 2009, Journal of cellular biochemistry.

[6]  Yin-Kai Chen,et al.  The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles. , 2009, Biomaterials.

[7]  P. Wielopolski,et al.  Cell labelling with superparamagnetic iron oxide has no effect on chondrocyte behaviour. , 2009, Osteoarthritis and cartilage.

[8]  B. Strauer,et al.  The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. , 2009, Journal of the American College of Cardiology.

[9]  Youngju Kim,et al.  MRI tracking of intravenously transplanted human neural stem cells in rat focal ischemia model , 2009, Neuroscience Research.

[10]  F. Ris,et al.  Clinical Magnetic Resonance Imaging of Pancreatic Islet Grafts After Iron Nanoparticle Labeling , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  M. Neri,et al.  Efficient In Vitro Labeling of Human Neural Precursor Cells with Superparamagnetic Iron Oxide Particles: Relevance for In Vivo Cell Tracking , 2008, Stem cells.

[12]  Liangfu Zhou,et al.  Tracking neural stem cells in patients with brain trauma. , 2006, The New England journal of medicine.

[13]  A. Akbar,et al.  Mantoux Test as a model for a secondary immune response in humans. , 2006, Immunology letters.

[14]  A. Arbab,et al.  Expression of transferrin receptor and ferritin following ferumoxides–protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging , 2006, NMR in biomedicine.

[15]  Y. Ni,et al.  In vitro labeling and MRI of mesenchymal stem cells from human umbilical cord blood. , 2006, Magnetic resonance imaging.

[16]  M. Cerqueira,et al.  Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. , 2006, The American journal of cardiology.

[17]  A. Arbab,et al.  Labeling of cells with ferumoxides–protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells , 2005, NMR in biomedicine.

[18]  Arend Heerschap,et al.  Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy , 2005, Nature Biotechnology.

[19]  T. Coates,et al.  MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. , 2005, Blood.

[20]  Jeff W M Bulte,et al.  Chondrogenic differentiation of mesenchymal stem cells is inhibited after magnetic labeling with ferumoxides. , 2004, Blood.

[21]  Jeff W M Bulte,et al.  Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis , 2004, NMR in biomedicine.

[22]  W. Vaughn,et al.  Improved Exercise Capacity and Ischemia 6 and 12 Months After Transendocardial Injection of Autologous Bone Marrow Mononuclear Cells for Ischemic Cardiomyopathy , 2004, Circulation.

[23]  Heather Kalish,et al.  Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. , 2004, Blood.

[24]  Bernd Hertenstein,et al.  Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial , 2004, The Lancet.

[25]  Heather Kalish,et al.  Comparison of Transfection Agents in Forming Complexes with Ferumoxides, Cell Labeling Efficiency, and Cellular Viability , 2004, Molecular imaging.

[26]  Ergin Atalar,et al.  In Vivo Magnetic Resonance Imaging of Mesenchymal Stem Cells in Myocardial Infarction , 2003, Circulation.

[27]  A. Kaider,et al.  Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study , 2009, Nature Clinical Practice Cardiovascular Medicine.

[28]  G. Dai,et al.  Superparamagnetic iron oxide does not affect the viability and function of adipose-derived stem cells, and superparamagnetic iron oxide-enhanced magnetic resonance imaging identifies viable cells. , 2009, Magnetic resonance imaging.

[29]  H. Fine,et al.  Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. , 2005, Blood.